NCT06309667View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions

HealthyOverweight

Interventions

DRUG

PG-102(MG12)

GLP-1 and GLP-2 fusion protein

OTHER

Placebo

Placebo drug of PG-102(MG12)

Trial Locations (1)

06591

Catholic University Seoul St.Mary Hospital,, Seocho

All Listed Sponsors

lead

ProGen. Co., Ltd.

OTHER

NCT06309667 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. | Biotech Hunter | Biotech Hunter